News about Global Pharma

Biosyngen's BST02 Receives Fast Track Designation for Liver Cancer Treatment

Fast Track Designation is a special process designed to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions, addressing unmet medical needs.

Global Pharma | 03/02/2024 | By Manvi |  383

NeuroBo Pharmaceuticals Receives FDA Clearance for Phase 1 Trial of DA-1726 in Obesity Treatment

The company is set to commence a Phase 1 clinical trial for obesity treatment in the first half of this year.

Global Pharma | 03/02/2024 | By Manvi |  459

FM Sitharaman Unveils Transformative Healthcare Measures in Interim Budget 2024

To address structural deficiencies in the healthcare system, the budget outlines plans to set up additional medical colleges by leveraging existing hospital infrastructure under various departments.

Global Pharma | 02/02/2024 | By Manvi |  519

Nippon Express Strengthens Pharmaceutical Logistics with CEIV Pharma Certification

The certification, issued by the International Air Transport Association (IATA), attests to the high quality and standards of pharmaceutical transport.

Global Pharma | 01/02/2024 | By Manvi |  618

Kite's Yescarta CAR T-Cell Therapy Gets FDA Nod for Manufacturing Process Change

In the realm of CAR T-cell therapies, where personalized treatment is created from a patient's white blood cells, the approval marks a significant advancement.

Global Pharma | 31/01/2024 | By Manvi |  552

NeoImmuneTech's NT-I7 Receives FDA ODD for Advanced Pancreatic Cancer Treatment

Pancreatic cancer is an aggressive tumor-type associated with extremely poor prognosis.

Global Pharma | 30/01/2024 | By Manvi |  547

Alcami Strengthens Market Position with Acquisition of Pacific Pharmaceutical Services

In addition to the acquisition of PPS, Alcami is strategically expanding its central North Carolina pharma storage and service footprint with the opening of a new 65,000 square foot facility co-located near the Research Triangle Park's biotech and pharma hub.

Global Pharma | 30/01/2024 | By Manvi |  462

Jubilant Pharma Plans Strategic Exit from Sofie Biosciences

The pharmaceutical giant's wholly-owned subsidiary had previously invested USD 25 million in Sofie Biosciences in November 2020, currently holding a noteworthy 25.8 percent stake in the company.

Global Pharma | 29/01/2024 | By Manvi |  241

Lutathera Breakthrough: 72 Percent Reduction in Gastroenteropancreatic Neuroendocrine Tumor Progression

The trial's efficacy endpoints further underscore the superiority of Lutathera, with a progression-free survival hazard ratio of 0.28 and a median progression-free survival of 22.8 months, significantly outperforming high-dose octreotide LAR.

Global Pharma | 29/01/2024 | By Manvi |  578

Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe

This first-in-class PRS inhibitor has recently received 'Orphan Drug Designation (ODD)' from the European Medicines Agency (EMA), adding to its earlier designation by the US FDA for both IPF and systemic sclerosis.

Global Pharma | 29/01/2024 | By Manvi |  425